Do you want to read an article? Please log in or register.
Long-Term Outcomes of Treatment with Biological Agents in Eyes with Refractory, Active, Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis
Uveitis
Related content
COMMENTED
Uveitis
Long-Term Safety and Efficacy of Adalimumab in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis
★ 2
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
Ophthalmology
Suhler EB, Jaffe GJ, Fortin E, Lim LL, Merrill PT, Dick AD, Brezin AP, Nguyen QD, Thorne JE, Van Calster J, Cimino L, Adan A, Goto H, Kaburaki T, Kramer M, Vitale AT, Kron M, Song AP, Liu J, Pathai S, Douglas KM, Schlaen A, Muccioli C, Van Velthoven MEJ, Zierhut M, Rosenbaum JT
doi: 10.1016/j.ophtha.2020.10.036
Uveitis
Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials
JAMA Ophthalmol.
Sheppard J, Joshi A, Betts KA, Hudgens S, Tari S, Chen N, Skup M, Dick AD
Glaucoma and Ocular PressureMacular DiseasesOcular OncologyUveitis
Long Term Outcomes of Pediatric Idiopathic Intermediate Uveitis: Outcomes of Pediatric Intermediate Uveitis
Am J Ophthalmol
AlBloushi AF, Solebo AL, Gokhale E, Al-Hayouti H, Ajamil-Rodanes S, Petrushkin H
doi: 10.1016/j.ajo.2021.11.003
Retinal DiseasesUveitis
Predictors of Long-Term Visual Outcome in Intermediate Uveitis.
Ophthalmology.
Niederer RL, Sharief L, Bar A, Lightman SL, Tomkins-Netzer O
doi: 10.1016/
Uveitis
Incidence and outcome of uveitic glaucoma in eyes with intermediate, posterior or panuveitis followed up to 10 years after randomization to fluocinolone acetonide implant or systemic therapy
Am J Ophthalmol.
Kempen JH, Van Natta ML, Friedman DS, Altaweel MM, Ansari H, Dunn JP, Elner SG, Holbrook JT, Lim LL, Sugar EA, Jabs DA, Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study Research Group
doi: 10.1016/j.ajo.2020.06.038.
Uveitis
Association Between Long-Lasting Intravitreous Fluocinolone Acetonide Implant vs Systemic Anti-inflammatory Therapy and Visual Acuity at 7 Years Among Patients With Intermediate, Posterior, or Panuveitis
JAMA.
Writing Committee for the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study Research Group, Kempen JH, Altaweel MM, Holbrook JT, Sugar EA, Thorne JE, Jabs DA
doi: 10.1001/
Uveitis
Efficacy and Safety of Intravitreal Sirolimus for Noninfectious Uveitis of the Posterior Segment: Results from the Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) Program
Ophthalmology.
Merrill PT, Clark WL, Banker AS, Fardeau C, Franco P, LeHoang P, Ohno S, Rathinam SR, Ali Y, Mudumba S, Shams N, Nguyen QD, Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) Study Group.
doi: 10.1016/j.ophtha.2020.03.033.
Uveitis
Adalimumab in Patients with Active Noninfectious Uveitis
N Engl J Med.
Jaffe GJ, Dick AD, Brézin AP, Nguyen QD, Thorne JE, Kestelyn P, Barisani-Asenbauer T, Franco P, Heiligenhaus A, Scales D, Chu DS, Camez A, Kwatra NV, Song AP, Kron M, Tari S, Suhler EB
doi: 10.1056/
Macular DiseasesRetinal DiseasesUveitis
Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients
Clin Rheumatol.
Fabiani C, Vitale A, Rigante D, Emmi G, Bitossi A, Lopalco G, Sota J, Guerriero S, Orlando I, Gentileschi S, Iannone F, Frediani B, Galeazzi M, Vannozzi L, Tosi GM, Cantarini L
doi: 10.1007/s10067-018-4228-6.